Pulse Explorar nav.journalClub Debates Tendencias Investigadores

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

Inicio Explorar nav.journalClub Tendencias

⌘+K

Alemtuzumab CARE-MS I 5-year follow-up | Synapse

August 24, 2017Open Access

Alemtuzumab CARE-MS I 5-year follow-up

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

This study provides Class III evidence that alemtuzumab durably improves efficacy outcomes and slows BVL in patients with RRMS.

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Cite This Study

Havrdová et al. (Thu,) studied this question.

synapsesocial.com/papers/69df06bbd5404a0bea5916fc https://doi.org/https://doi.org/10.1212/wnl.0000000000004313

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Shifting the paradigm toward earlier treatment of multiple sclerosis with interferon beta2009 · 47 citations
2Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis2008 · 894 citations
3Relationship between brain atrophy and disability: an 8-year follow-up study of multiple sclerosis patients2000 · 178 citations
4Defining the clinical course of multiple sclerosis2014 · 3,145 citations
5RRMS Patients Switching from SC IFNB-1a to Alemtuzumab in the CARE-MS I and II Extension Study Have a Reduced Rate of Brain Volume Loss (P6.183)2016 · 2 citations